Go to BioCentury homepage
Print this Print this
Welcome to BCIQ: BioCentury Online Intelligence.
Free access to this and other abridged company profiles is provided to all subscribers to SciBX: Science-Business eXchange.

Please explore the profile and if you wish to find out more about BCIQ - please Click Here

Spectrum Pharmaceuticals Inc.

Print preview Print preview

(NASDAQ:SPPI)
formerly known as NeoTherapeutics Inc.

Collapse Summary

General Information
 Location Irvine, Calif.
 Region Los Angeles/Orange County
 Country U.S.
 Business Category Cancer, Genitourinary, Neurology
 Year Founded 1987
 Website www.spectrumpharm.com
 Development Status

Archive Items are loading
Collapse Summary

Financial Information
Total Money RaisedNumber of Completed FinancingsLast Financing DateLast Financing TypeNumber of All Financings

$259,946,710

24

06/18/2009

Direct public units (other)

25

Financing Details (25 records)

Company NameFinancing StatusDate CompletedFinancing TypeAmount RaisedShare PricePost-Money Valuation

Spectrum Pharmaceuticals Inc.

Completed

06/18/2009

Direct public units (other)

$10,000,001

$5.83 (unit)

$0

Spectrum Pharmaceuticals Inc.

Completed

05/29/2009

Direct public units (other)

$20,000,000

$5.11 (unit)

$0
More

Financial Performance Summary

1Q082Q083Q084Q081Q09

As Of Date

03/31/2008

06/30/2008

09/30/2008

12/31/2008

03/31/2009

Profit and loss

     

Sales

     

Revenues

$0

$20,676,000

$0

$8,049,000

$14,163,000

SG&A

$2,585,000

$3,230,000

$3,132,000

$6,214,000

$6,351,000

R&D

$6,382,000

$6,747,000

$5,960,000

$7,594,000

$5,654,000

Operating Income

($8,967,000)

$10,699,000

($9,092,000)

($11,810,000)

($626,000)

Net Income

($8,666,000)

$10,678,000

($8,816,000)

($8,663,000)

$624,000

EPS

-$0.28

$0.34

-$0.28

-$0.27

$0.02

Diluted EPS

 

$0.34

  

$0.02

Shares Outstanding

31,271,000

31,463,000

31,538,000

31,929,000

32,440,000

Balance Sheet

     

Cash

$48,586,000

$59,550,000

$51,636,000

$78,086,000

$63,898,000

Valuations

     

Market Cap

$79,115,630

$43,733,570

$44,468,580

$47,574,210

$56,770,000

Tech Value

$30,529,630

($15,816,430)

($7,167,420)

($30,511,790)

($7,128,000)

R&D/Sales

     

R&D/Revenue

 

0.33

 

0.94

0.40

SG&A/Sales

     

SG&A/Revenue

 

0.16

 

0.77

0.45

Currency Rate

     

Rate

1.0000

1.0000

1.0000

1.0000

1.0000

Stocks Annual Chart

Week of 03/13/2009 - 474,240 Week of 03/06/2009 - 846,840 Week of 02/27/2009 - 750,776 Week of 04/03/2009 - 1,218,012 Week of 03/27/2009 - 1,634,409 Week of 03/20/2009 - 715,010 Week of 02/20/2009 - 946,255 Week of 01/23/2009 - 298,391 Week of 01/16/2009 - 427,378 Week of 01/09/2009 - 379,299 Week of 02/13/2009 - 1,295,753 Week of 02/06/2009 - 817,224 Week of 01/30/2009 - 664,802 Week of 06/12/2009 - 4,385,501 Week of 06/05/2009 - 2,629,859 Week of 05/29/2009 - 2,634,859 Week of 07/02/2009 - 18,296,357 Week of 06/26/2009 - 15,994,586 Week of 06/19/2009 - 6,975,990 Week of 05/22/2009 - 3,815,677 Week of 04/24/2009 - 1,095,018 Week of 04/17/2009 - 1,832,001 Week of 04/10/2009 - 2,072,040 Week of 05/15/2009 - 3,966,602 Week of 05/08/2009 - 3,605,811 Week of 05/01/2009 - 1,274,114 Week of 01/02/2009 - 66,579 Week of 09/12/2008 - 468,100 Week of 09/05/2008 - 213,731 Week of 08/29/2008 - 561,363 Week of 10/03/2008 - 540,042 Week of 09/26/2008 - 507,622 Week of 09/19/2008 - 434,174 Week of 08/22/2008 - 672,964 Week of 07/25/2008 - 578,890 Week of 07/18/2008 - 413,465 Week of 07/11/2008 - 464,584 Week of 08/15/2008 - 1,090,294 Week of 08/08/2008 - 265,587 Week of 08/01/2008 - 262,280 Week of 12/12/2008 - 552,882 Week of 12/05/2008 - 1,911,907 Week of 11/28/2008 - 664,489 Week of 12/31/2008 - 303,181 Week of 12/26/2008 - 178,539 Week of 12/19/2008 - 486,057 Week of 11/21/2008 - 1,031,747 Week of 10/24/2008 - 266,008 Week of 10/17/2008 - 732,399 Week of 10/10/2008 - 1,021,067 Week of 11/14/2008 - 557,524 Week of 11/07/2008 - 876,650 Week of 10/31/2008 - 2,031,910
Collapse Summary

Pipeline Information
Disease CategoryResearchPhase IPhase I/IIPhase IIPhase II/IIIPhase IIIRegistrationApprovedMarketed
Cancer

2

3

-

4

-

1

1

1

2

Genitourinary

1

-

-

1

-

-

-

-

-

Neurology

4

-

-

-

-

-

-

-

-

Renal

1

-

-

-

-

-

-

-

-

Total

8

3

-

5

-

1

1

1

2

Pipeline Details - Originated and out-licensed products (13 records)

Product Names

Disease Category

Standard Indication

Partners

Milestones

Latest Stage of Development

Elsamitrucin (Informal)

Cancer

Non-Hodgkin's lymphoma (NHL)

 

 

Phase II

Elsamitrucin (Informal)

Cancer

Solid tumors

 

 

Phase I
More

Pipeline Details - In-licensed products (8 records)

Product NamesDisease CategoryStandard IndicationIn-licensed fromMilestonesLatest Stage of DevelopmentRights

14-beta-hydroxydeacetylbaccatin (Chemical), SPI-5109 (Compound #), IDN 5109 (Former compound #), ortataxel (Generic)

Cancer

Non-small cell lung cancer (NSCLC)

Indena S.p.A.

 

Phase II

Full

D-63153 (Compound #), SPI-153 (Compound #), ozarelix (Generic)

Cancer

Prostate cancer

Aeterna Zentaris Inc.

 

Phase II

Full
More